CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 235 enrolled
Drug / intervention
Neostigmine +1 moredrug
Likely dose
Rocuronium boluses for neuromuscular blockade maintenance; reversal with either neostigmine or sugammadex (specific doses not stated)AI-extracted
Key inclusion· 6
  • Age 18-80 years
  • Undergoing laparoscopic cholecystectomy
  • Anticipated surgical duration less than 2 hours
  • ASA physical status classification 1-3
Key exclusion· 12
  • Preoperative urinary catheter
  • History of problems with urination
  • Current use of anticholinergic medications (antihistamines, phenothiazines, antidepressants, antipsychotics)
  • Current UTI or urogenital problem (incontinence, bladder retention, prostate hypertrophy)

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05794503
NCT05794503Phase 4Completed

Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Controlled Trial

University of Texas Southwestern Medical Center·interventional·Posted Apr 3, 2023·Updated Oct 9, 2024

In Brief

A Phase 4 clinical trial evaluating Neostigmine and Sugammadex for Urinary Retention Postoperative and 6 related conditions. Completed, enrolled 235 participants across 1 site.

Detailed Summary

This study is intended to be a single-site, prospective, randomized, controlled study that intends to enroll a total of 230 patients undergoing laparoscopic cholecystectomy at Parkland Hospital. Patients will be randomized to receive either neostigmine or sugammadex for reversal of rocuronium-induced neuromuscular blockade. A standardized anesthetic protocol that is usual and customary for the type of operation the patient is having will be provided to the anesthesia teams of enrolled subjects. The remainder of the anesthetic care of the subject will not deviate from the standard of care. To account for protocol deviations and patient dropout, up to 250 randomization envelopes will be made and enrollment will continue until there are 230 completed enrollments.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedApr 3, 2023
Enrollment StartSep 11, 2023
Primary CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 3.2 years ago

Interventions

Neostigminedrug

Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, neostigmine.

Sugammadexdrug

Maintenance neuromuscular blockade with boluses of rocuronium. For reversal, sugammadex